Video

Dr. Reck on Safety Data From the CheckMate-9LA Trial in Metastatic/Recurrent NSCLC

Author(s):

Martin Reck, MD, PhD, discusses ​safety data from the ​phase 3 CheckMate-9LA trial in metastatic or recurrent non–small cell lung cancer.

Martin Reck, MD, PhD, head of the department of thoracic oncology at Lung Clinic Grosshansdorf, discusses ​safety data from the ​phase 3 CheckMate-9LA trial in metastatic or recurrent non–small cell lung cancer (NSCLC).

Findings from the study suggest that the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) plus 2 cycles of platinum-doublet chemotherapy ​should be considered an option for this patient population.

However, it is an intensive regimen, says Reck. Moreover, treatment-emergent adverse effects (AEs) were observed more frequently with the experimental regimen compared with chemotherapy alone.

Treatment-related deaths occurred in 2% of patients in both arms.

Notably, the incidence of chemotherapy-related AEs including hematologic AEs was lower in the combination arm ​as patients received 2 ​cycles ​of chemotherapy versus 4, Reck concludes.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation
Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Jun 6th 2025 - Jul 12th 2025

online-activity
Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC
Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Jun 6th 2025 - Jul 12th 2025

online-activity
Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing
Video

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Jun 5th 2025 - Jul 12th 2025

online-activity